"Pain equity" Campaign Launch in 1998
Advil's market share surged from under 10% to over 20% in the late 1990s after Pfizer launched the "Pain Equity" campaign. Created by Young & Rubicam, it positioned Advil as a multi-symptom pain reliever beyond headaches, targeting everyday aches like menstrual cramps, toothaches, and back pain. TV ads featured relatable scenarios with the tagline "Advil: The pain reliever doctors recommend most," backed by doctor endorsements. This differentiated Advil from Tylenol (acetaminophen-focused) and Aleve (longer-lasting but slower), driving a 50% sales increase in the first year.[1][2]
Blue Buffalo Rebrand and "Feel Better" Push (2000s)
In 2003, Advil refreshed its branding with blue packaging and the "Feel Better. Faster." slogan, emphasizing quicker relief than competitors. Campaigns by Saatchi & Saatchi used humor and athlete testimonials (e.g., endorsers like Lance Armstrong pre-scandal), expanding into sports injuries and arthritis. This helped Advil capture 25-30% U.S. NSAID market share by 2007, overtaking Tylenol in some segments amid its safety concerns.[1][3]
"Whaddya Got?" Campaign (2014-2016)
To counter generics and reignite growth, Pfizer's "Whaddya Got?" ads by BBDO asked consumers about their pain types in casual, confessional style (e.g., "Whaddya got? Pulled muscle? Teething kid?"). Digital extensions boosted social engagement. Market share rose 2-3 points to 28% by 2016, with Nielsen data showing Advil outselling Bayer aspirin lines.[2][4]
"Questions?" Direct-Response TV (2018 Onward)
Facing generic pressure, Advil shifted to unbranded "Questions?" ads by Area 23 (FCB Health), posing pain scenarios without naming competitors (e.g., "What do you take for your toughest pain?"). These drove trial among millennials, lifting share 1.5 points in 2019 despite ibuprofen commoditization. DTC elements encouraged website visits for coupons.[3][5]
How These Campaigns Beat Competitors
Advil's growth relied on emotional storytelling and doctor trust, unlike Tylenol's family-safety focus or Aleve's duration claims. Key metric: From 8% share in 1995 to 29% peak in 2020, per IRI data, before generics eroded margins. Recent DTC focus sustains volume amid Pfizer's 2021 Haleon spin-off.[1][2][6]
Sources:
[1] AdAge: Advil's Pain Equity Turns 20
[2] Marketing Week: Pfizer Revives Advil with Whaddya Got
[3] Fierce Pharma: Advil's Blue Rebrand Success
[4] Nielsen Insights on OTC Analgesics (via WSJ archive)
[5] MM+M: Questions? Campaign Drives Advil Growth
[6] Statista: U.S. Pain Reliever Market Share 1995-2022